Antineoplastic agents induce oxidative stress in biological systems. During cancer chemotherapy, oxidative stressinduced lipid peroxidation generates numerous electrophilic aldehydes that can attack many cellular targets. These products of oxidative stress can slow cell cycle progression of cancer cells and cause cell cycle checkpoint arrest, effects that may interfere with the ability of anticancer drugs to kill cancer cells. The aldehydes may also inhibit drug-induced apoptosis (programmed cell death) by inactivating death receptors and inhibiting caspase activity. These effects would also diminish the efficacy of the treatment. The use of antioxidants during chemotherapy may enhance therapy by reducing the generation of oxidative stress-induced aldehydes.
Reactive oxygen species (ROS) are essential for life because of their role in many vital processes such as signal transduction and the ability of phagocytes to carry out their bactericidal activity. ROS include free radicals, such as hydroxyl and superoxide radicals, which are substances with one or more orbital electrons with unpaired spin states, and nonradicals, including hydrogen peroxide and singlet oxygen ( Table 1) . Although carefully controlled processes regulate the production of ROS for their essential functions, many cellular processes result in the generation of ROS. An important site of this nonessential generation of ROS, which constitutes oxidative stress, is the electron transport system (ETS; Figure 1 ) that resides within the inner membrane of mitochondria. Normally, electrons are transferred from complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase) to coenzyme Q10 and then to complex III, cytochrome c, and complex IV. Finally, 4 electrons are transferred to oxygen with the formation of water. In the process, coupling of electron transport to oxidative phosphorylation results in adenosine triphosphate generation. Although this process is very efficient, about 2% of the electrons escape the ETS and react with molecular oxygen to form superoxide radicals. Although superoxide is not highly toxic, mitochondrial superoxide dismutase generates hydrogen peroxide from superoxide radicals, and, in the presence of reduced iron or copper, the highly toxic hydroxyl radical is formed via Fenton or Haber-Weiss reactions. The cytochrome P450 monooxygenase system of the hepatic endoplasmic reticulum (microsomes) also generates a substantial amount of ROS in the process of metabolizing a chemically diverse group of compounds that includes most of the drugs that we administer as well as environmental substances. The plasma and nuclear membranes are less active sites of ROS production, and enzyme systems, such as the xanthine-xanthine oxidase system, can also generate ROS.
ROS can interact with cellular macromolecules, including DNA, protein, and lipids, and interfere with vital cellular functions. Mutations caused by ROS can result in malignant transformation and the development of cancer. ROS are also implicated in the etiology and progression of many other diseases. Under normal conditions, antioxidant mechanisms, including small-molecular-weight antioxidants and antioxidant enzyme systems, scavenge ROS and protect the organism from the damaging effects of oxidative stress. However, under conditions of excessive oxidative stress, for example, those which occur with the administration of certain drugs, cellular antioxidant mechanisms may be unable to prevent the adverse impact of ROS on critical cellular processes. In cancer cells, processes such as the ordered progression through the cell cycle and intact apoptotic processes are necessary for antineoplastic agents to exert their optimal cytotoxic activity. Since many antineoplastic agents are capable of producing oxidative stress in biological systems, ROS generated during cancer chemotherapy may interfere with the efficacy of the treatment.
Chemotherapy-Associated Oxidative Stress
Antineoplastic agents have been shown to produce oxidative stress in patients who receive these drugs during cancer chemotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This is evident by the elevation of lipid peroxidation products; the reduction of total radical-trapping capacity of blood plasma; the reduction in plasma levels of antioxidants such as vitamin E, vitamin C, and β-carotene; and the marked reduction of tissue glutathione levels that occurs during chemotherapy. Those agents that generate high levels of ROS include the anthracyclines (eg, doxorubicin, epirubicin, and daunorubicin), alkylating agents, platinum coordination complexes (eg, cisplatin, carboplatin, and oxaliplatin), epipodophyllotoxins (eg, etoposide and teniposide), and the camptothecins (eg, topotecan and irinotecan; Figure 2). The anthracyclines generate by far the highest levels of oxidative stress. This is due to their ability to divert electrons from the ETS of cardiac mitochondria, resulting in formation of superoxide radicals, 12 in addition to generating ROS at other cellular sites. Doxorubicin, the most studied anthracycline, possesses a sugar moiety attached to a tetracycline ring that contains a quinone structure. Disruption of the ETS by doxorubicin can occur only following reduction of the quinone to its semiquinone. Doxorubicin is hydrophilic and, in mitochondria of most cells, it cannot penetrate the inner membrane and be reduced by NADH dehydrogenase (complex I), which is located on the inner (matrix) surface. However, the structure of the cardiac mitochondria inner membrane is unique in that it possesses an NADH dehydrogenase on the outer (cytosolic) surface in addition to the matrix NADH dehydrogenase that is present in mito-chondria of all cells. 13 In cardiac cells, doxorubicin can penetrate the outer mitochondrial membrane and enter the cytosol where it is reduced by the cytosolic NADH dehydrogenase. Intramolecular rearrangement results in formation of the lipophilic deoxyaglycone of doxorubicin that penetrates the inner membrane. There it competes with coenzyme Q10 (both are structurally quinones) as an electron acceptor, diverting electrons to molecular oxygen with the formation of superoxide radicals.
In contrast to the above groups of antineoplastic agents, taxanes (eg, paclitaxel and docetaxel), vinca alkaloids (eg, vincristine and vinblastine), antimetabolites such as the antifolates, and nucleoside and nucleotide analogues generate only low levels of oxidative stress ( Figure 2 ). However, all antineoplastic agents generate some ROS as they induce apoptosis in cancer cells. This is because one of the pathways of drug-induced apoptosis involves the release of cytochrome c from mitochondria. 14 When this occurs, electrons are diverted from the ETS to oxygen by NADH dehydrogenase and reduced coenzyme Q10, resulting in the formation of superoxide radicals.
Oxidative stress interferes with cellular processes (cell cycle progression and drug-induced apoptosis; see below) that are necessary for antineoplastic agents to exert their optimal cytotoxicity on cancer cells, and modest levels of oxidative stress have been shown to reduce the cytotoxicity of anticancer drugs. 15, 16 Thus, the formation of ROS that occurs when anticancer drugs are administered may diminish the effectiveness of the treatment. In addition, since some side effects caused by antineoplastic agents appear to be prevented by certain antioxidants, administering these supplements during chemotherapy may diminish the Figure 1 The electron transport system. Electrons flow from complex I (NADH dehydrogenase) and complex II (succinate dehydrogenase) to coenzyme Q10, then to complex III, cytochrome c, and complex IV. The final transfer is a 4electron transfer to oxygen with the formation of water. The electron transport system is coupled at 3 sites to oxidative phosphorylation that results in the formation of adenosine triphosphate (ATP).
development of side effects as well as improve the response to therapy. This contention is supported by many preclinical and some clinical studies.
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Mediators of Oxidative Stress
Free radicals (Table 1 ) generated during oxidative stress have many cellular targets, although one of the primary targets is cellular lipids. Lipid peroxidation of polyunsaturated fatty acids results in the formation of peroxyl and alkoxyl radicals. These primary products of lipid peroxidation, which are highly reactive and relatively short-lived, undergo further reactions to form secondary products of lipid peroxidation that include a variety of aldehydes (Table 1 ) such as malondialdehyde, the 4-hydroxyalkenals, and acrolein. 19 The aldehydes are more stable than the primary products and can diffuse throughout the cell where they damage cellular components and interfere with cellular functions. Because of their electrophilic character, the aldehydes bind to nucleophilic groups of amino acids, such as cysteine, lysine, histidine, serine, and tyrosine, which are critical components of enzyme active sites or are necessary for maintaining the tertiary structure of proteins. The binding of aldehydes to proteins, which results in enzyme inhibition and alteration of the structure of cellular receptors, may account for the impact of oxidative stress on the cytotoxicity of antineoplastic agents.
The Cell Cycle
The cell cycle (Figure 3 ) consists of 4 phases: G1, S, G2, and M. During G1, the cell prepares for DNA synthesis. The S phase is the phase of DNA synthesis. During G2, the cell prepares for mitosis. The M phase is the phase of mitosis during which the cell divides into 2 daughter cells. The major regulatory points and safeguards of the cell cycle include the restriction point (R) and the checkpoints (C). A cardinal feature of the normal cell cycle is strict control of the cellular decision to advance to another round of DNA synthesis. In the presence of mitogens and when other requirements, such as the presence of adequate nutrients, are met, the cell will pass the restriction point and is committed to another round of DNA synthesis. The checkpoints, which ensure that the integrity of the genome is maintained, include the G1 and G2 checkpoints, which arrest the cell cycle if DNA damage is detected; the S phase checkpoint, which arrests the cell cycle if a problem with DNA replication occurs; and the M phase checkpoint, which arrests the cell cycle if a problem with mitotic spindle assembly occurs. When the cell cycle arrests at a checkpoint, the cell either cor- Figure 2 Oxidative stress and chemotherapy. The highest level of oxidative stress induced by antineoplastic agents is seen with the anthracyclines. This is due to their unique ability to generate reactive oxygen species in cardiac mitochondria. Platinum coordination complexes, alkylating agents, epipodophyllotoxins, and camptothecins also generate high levels of oxidative stress at multiple cellular sites. Nucleoside and nucleotide analogues, antifolates, taxanes, and vinca alkaloids generate only low levels of oxidative stress, which occurs primarily as a result of drug-induced apoptosis. rects the defect that is detected (eg, by repairing damaged DNA) or undergoes apoptosis.
Oxidative stress reduces the rate of cell proliferation by inhibiting the transition of cells from the G0 to the G1 phase, prolonging the G1 phase, slowing progression through the S phase by inhibiting DNA synthesis, inhibiting cell cycle progression through the restriction point, and causing arrest at cell cycle checkpoints. [19] [20] [21] [22] [23] [24] [25] Thus, the rate of proliferation of cells in culture (normal cells and cancer cells) decreases during periods of oxidative stress, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and oxidative stress slows the growth of tumors in laboratory animals. [37] [38] [39] The 4hydroxyalkenals, specifically, have been shown to inhibit tumor cell growth in culture 40 and in laboratory animals. 41 Other studies clearly demonstrate that high rates of growth of normal tissue (liver) 42, 43 and tumors 20, 44 are associated with low levels of lipid peroxidation. Thus, it is not surprising that tumor cells have diminished levels of pro-oxidant enzymes and efficient antioxidant systems so that they can maintain a low level of intracellular oxidative stress and a rapid rate of proliferation. [45] [46] [47] [48] [49] [50] The effects of oxidative stress on cell proliferation are most likely attributable to inhibition of critical enzymes by the aldehydes, and selective inhibition of DNA polymerases by 4-hydroxyalkenals has been demonstrated. 21, [51] [52] [53] The cyclin-dependent kinases (CDKs) are other likely targets of the aldehydes. These enzymes (Figure 4 ) ensure an ordered progression through the phases of the cell cycle, and their inhibition, for example, by the CDK inhibitor p21 (the mediator of the p53 tumor suppressor gene), prevents passage through the restriction point and causes checkpoint arrest ( Figure  5 ). 23 Antineoplastic agents that exhibit cell cycle phasespecific activities depend on cell cycle progression to exert their antineoplastic activity, and interference with this progression will diminish the cytotoxicity of the drugs. Examples of agents that exhibit phase-specific activities include (1) anthracyclines and epipodophyllotoxins that inhibit topoisomerase II activity and act in the S phase, (2) antifolates and nucleotide/nucleoside analogues that interfere with DNA synthesis and act in the S phase, (3) vinca alkaloids and taxanes that interfere with the mitotic process and act primarily during the M phase, and (4) camptothecins that inhibit topoisomerase I activity and act in the S phase. Even platinum coordination complexes and alkylating agents, which are not considered to be phase-specific agents, require cells to progress through the S phase and G2 phase of the cell cycle for apoptosis to occur. In addition, repair of DNA damage caused by platinum coordination complexes and alkylating agents results in resistance to these drugs, and checkpoint arrest during oxidative stress may enhance the repair processes and diminish the efficacy of the treatment. [54] [55] [56] In this regard, checkpoint abrogation, the opposite of what occurs during oxidative stress, has been shown to enhance the cytotoxicity of most antineoplastic agents. By reducing the generation of aldehydes, antioxidants may counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of antineoplastic agents.
Drug-Induced Apoptosis
The 2 major cellular pathways of drug-induced apoptosis are the mitochondrial pathway, initiated by release of cytochrome c, and the CD95 death receptor pathway, initiated by ligation of the death receptor by its ligand CD95L ( Figure 6 ). 14, 57, 58 Following the initiating event, the apoptotic process is carried out by a family of enzymes called caspases. 59 Caspases (cysteinedependent aspartate directed proteases) are proteases that have a cysteine residue at the active site and require a reducing environment for optimal activity. The proapoptotic signals of CD95 ligation (antineoplastic agents upregulate the receptor or induce expression of the ligand) or cytochrome c release activate initiator caspases (caspases-8 and -9, respectively) that subsequently activate the effector caspases (caspases-3, -6, and -7) that carry out disassembly of the cell. Oxidative stress can induce apoptosis by causing damage to cellular components (eg, DNA), and some studies suggest that ROS are downstream mediators of apoptosis. 60 However, there is considerable evidence that apoptosis does not require ROS and that their generation is a late event after cells are already committed to programmed cell death. 61, 62 Consistent with this latter contention is the generation of ROS in mitochondria that occurs only after apoptosis is initiated by cytochrome c release.
Chemotherapy-Associated Oxidative Stress
In contrast to oxidative stress-induced apoptosis, excessive oxidative stress inhibits caspase activity [63] [64] [65] and drug-induced apoptosis, 15, 16 thereby interfering with the ability of antineoplastic agents to kill tumor cells. 15, 16 Caspase inhibition by other means, such as that caused by the cowpox virus CrmA protein when it is overexpressed in leukemia cells, has also been shown to confer resistance to a variety of antineoplastic agents. 66 Electrophilic aldehydes, such as the tetrapeptide aldehyde (acetyl-Tyr-Val-Ala-Asp-H) that was used to characterize caspase-1, covalently bind to the sulfhydryl group of the cysteine residue at the active site of caspases and inhibit their activity. 67 Thus, aldehyde generation, resulting in caspase inhibition, may account for the reduced efficacy of antineoplastic agents during oxidative stress. 15, 16 If so, antioxidants may enhance the anticancer activity of cancer chemotherapy by reducing aldehyde generation during chemotherapy-induced oxidative stress.
Aldehydes generated by lipid peroxidation during chemotherapy-induced oxidative stress may also directly interfere with the CD95 death receptor pathway of drug-induced apoptosis. The CD95 death receptor has a cysteine-rich extracellular domain, 68 making it a potential target for binding by strongly electrophilic agents such as the aldehydes. Binding of aldehydes to death receptors may mimic the effect of death receptor antibodies that bind the extracellular domain and interfere with ligand binding and druginduced apoptosis. Thus, antioxidants, by reducing the level of aldehydes, may facilitate drug-induced apoptosis via the CD95 pathway.
Conclusion
Oxidative stress interferes with many cellular functions, such as cell cycle progression and apoptotic pathways, that can reduce the ability of antineoplastic agents to kill cancer cells. The effects are mediated, most likely, by the many aldehydes that result from oxi- dative stress-induced lipid peroxidation. Since many drugs used for cancer chemotherapy cause oxidative stress, which can interfere with antineoplastic activity, reducing this oxidative stress by administering antioxidants may enhance the effectiveness of the treatment. However, enhancing the cytotoxicity of antineoplastic agents would affect normal cells as well as cancer cells. Thus, although certain antioxidants appear to prevent the development of some chemotherapy-induced side effects (coenzyme Q10 for anthracycline cardiotoxicity and glutathione for cisplatin nephrotoxicity 17 ), side effects that result from toxicity to rapidly proliferating normal cells, such as myelosuppression, hair loss, and mucositis (toxicity to enterocytes of the gastrointestinal tract), may also be enhanced by antioxidants. In this regard, vitamin E has been shown to enhance doxorubicin-induced myelosuppression in mice. 69 Certainly, further research is needed to fully elucidate the impact of single antioxidants and antioxidant combinations on the anticancer activity and side effects of individual drugs and the many drug combinations that are in clinical use.
